Capital asset pricing model (CAPM)
The capital asset pricing model has been widely used for many years by the global financial services industry to try and predict the returns you should expect from a stock.
The capital asset pricing model has been widely used for many years by the global financial services industry to try and predict the returns you should expect from a stock.
If a stock offers a return above that predicted by CAPM you should buy it, and vice versa. The starting point for a stock's expected return is the minimum 'risk free' return an investor should expect from medium-dated AAA government bonds, say 5%. You then add a premium, because stocks in general are riskier than bonds.
This figure is heavily debated, but let's say it is 3%. Now you adjust that extra premium for a stock's specific beta, say 1.2. So the expected CAPM return here would be 8.6% (5% + (3% x 1.2)). If you expect the stock you are reviewing to deliver, say, a 10% annual return, then it's a buy, says CAPM.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
See Tim Bennett's video tutorial: Warning: the City's formula for pricing shares is bust.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published